Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-Current Assets (2016 - 2025)

Guided Therapeutics' Non-Current Assets history spans 16 years, with the latest figure at $719000.0 for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 297.24% to $719000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $719000.0, a 297.24% increase, with the full-year FY2025 number at $719000.0, up 297.24% from a year prior.
  • Non-Current Assets hit $719000.0 in Q4 2025 for Guided Therapeutics, up from $104000.0 in the prior quarter.
  • Over the last five years, Non-Current Assets for GTHP hit a ceiling of $719000.0 in Q4 2025 and a floor of $104000.0 in Q3 2025.
  • Historically, Non-Current Assets has averaged $322450.0 across 5 years, with a median of $330500.0 in 2023.
  • Biggest five-year swings in Non-Current Assets: surged 570.97% in 2021 and later plummeted 49.51% in 2025.
  • Tracing GTHP's Non-Current Assets over 5 years: stood at $403000.0 in 2021, then fell by 10.17% to $362000.0 in 2022, then decreased by 23.76% to $276000.0 in 2023, then plummeted by 34.42% to $181000.0 in 2024, then skyrocketed by 297.24% to $719000.0 in 2025.
  • Business Quant data shows Non-Current Assets for GTHP at $719000.0 in Q4 2025, $104000.0 in Q3 2025, and $129000.0 in Q2 2025.